Nivolumab is a programmed death 1 (PD-1) inhibitor, and its combination with ipilimumab (cytotoxic T lymphocyte associated antigen-4 inhibitor) is superior to sunitinib in terms of OS and objective response rates in the treatment of patients with advanced ccRCC (36–39). The gene discussed is CTLA4; the disease is nonpapillary renal cell carcinoma.